These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 2081125)

  • 21. High-density lipoprotein cholesterol, hepatic lipase and lipoprotein lipase activities in thyroid dysfunction--effects of treatment.
    Lam KS; Chan MK; Yeung RT
    Q J Med; 1986 May; 59(229):513-21. PubMed ID: 3763814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pseudotumoral forms of multiple sclerosis.
    Kreindler A; Cardaş M; Petrescu A; Macovei M; Roşianu C
    Rev Roum Neurol; 1973; 10(6):569-77. PubMed ID: 4771096
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical multiple sclerosis occurs at one end of a spectrum of CNS pathology: a modified threshold liability model leads to new ways of thinking about the cause of clinical multiple sclerosis.
    Haegert DG
    Med Hypotheses; 2005; 65(2):232-7. PubMed ID: 15922093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medullasin activity in granulocytes of patients with multiple sclerosis.
    Aoki Y; Miyatake T; Shimizu N; Yoshida M
    Ann Neurol; 1984 Mar; 15(3):245-9. PubMed ID: 6372647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sensitized immunofixation: a new technique for analyzing the oligoclonal pattern of CSF immunoglobulins].
    Desplat S; Pelletier J; Pouget J; Bellon F; Bernard D; Boucraut J
    Rev Neurol (Paris); 2000 Oct; 156(10):885-9. PubMed ID: 11033517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis.
    Huang YH; Zozulya AL; Weidenfeller C; Metz I; Buck D; Toyka KV; Brück W; Wiendl H
    Ann Neurol; 2009 Aug; 66(2):171-83. PubMed ID: 19705413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study].
    Meca-Lallana JE; Rodríguez-Hilario H; Martínez-Vidal S; Saura-Luján I; Carretón-Ballester A; Escribano-Soriano JB; Martín-Fernández J; Genovés-Aleixandre A; Mateo-Bosch E; Fernández-Barreiro A
    Rev Neurol; 2003 Nov 16-30; 37(10):917-26. PubMed ID: 14634919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum prolactin level in patients with multiple sclerosis: a case control study.
    Harirchian MH; Sahraian MA; Shirani A
    Med Sci Monit; 2006 Apr; 12(4):CR177-80. PubMed ID: 16572053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Multiple sclerosis with negative cerebrospinal fluid. Magnetic resonance differential diagnosis].
    Bastianello S; Gasperini C; Ristori G; Paolillo A; Girmenia F; Bozzao L
    Radiol Med; 1994 Dec; 88(6):749-51. PubMed ID: 7878231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Behavior of lipoprotein lipase in multiple sclerosis and other neurologic diseases].
    Schär J
    Psychiatr Neurol (Basel); 1965; 150(2):92-103. PubMed ID: 5862931
    [No Abstract]   [Full Text] [Related]  

  • 31. [Lipase activities in the cerebrospinal fluid].
    Kluge H; Wieczorek V
    Psychiatr Neurol Med Psychol (Leipz); 1968 Sep; 20(9):340-2. PubMed ID: 5731889
    [No Abstract]   [Full Text] [Related]  

  • 32. [IgG synthesis in the central nervous system in multiple sclerosis and other neurologic diseases. Measurement and validity].
    Safár J; Vymazal J; Tichý J; Růzicková V
    Cas Lek Cesk; 1985 Sep; 124(36):1131-6. PubMed ID: 4028102
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pathologic decrease in lipoprotein lipase activity in relation to the development of hyperlipemias and their significance for coronary heart disease].
    Breier C
    Wien Klin Wochenschr Suppl; 1986; 167():1-16. PubMed ID: 3458343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Differential diagnosis of the clinical picture of multiple sclerosis in MR tomography].
    Gowin W; Mariss G
    Digitale Bilddiagn; 1986 Sep; 6(3):111-7. PubMed ID: 3769396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.
    Gijbels K; Masure S; Carton H; Opdenakker G
    J Neuroimmunol; 1992 Nov; 41(1):29-34. PubMed ID: 1334098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteolytic activity in CSF.
    Richards PT; Cuzner ML
    Adv Exp Med Biol; 1978; 100():521-7. PubMed ID: 80950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Identification of unspecific esterases in cerebrospinal fluid cells. An additional cytodiagnostic test].
    Olischer RM
    Z Neurol; 1971; 200(1):61-9. PubMed ID: 4108148
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum carnosinase activities in central nervous system disorders.
    Wassif WS; Sherwood RA; Amir A; Idowu B; Summers B; Leigh N; Peters TJ
    Clin Chim Acta; 1994 Feb; 225(1):57-64. PubMed ID: 8033354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoproteinlipase activity in multiple sclerosis and other neurologic diseases.
    Popoviciu L; Hobai S; Condrat A
    Rom J Neurol Psychiatry; 1990; 28(3):199-207. PubMed ID: 2081125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chronic inflammatory demyelinating polyradiculoneuropathy associated with central nervous system involvement--as compared to multiple sclerosis].
    Komori T; Ohtake T; Miyazaki Y; Hirose K; Tanabe H
    Rinsho Shinkeigaku; 1990 Sep; 30(9):939-43. PubMed ID: 2265502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.